Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
29 févr. 2024 07h30 HE
|
Arbutus Biopharma Corporation
On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical...
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
15 févr. 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...